Year 2011,
Volume: 24 Issue: 3, 200 - 202, 21.04.2015
Abstract
-
Keywords
References
- 1. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004:31-40 doi:10.1016/j.ejon.2004.06.007
- 2. Turkmen M, Gerceker Turk B, Kılınc Kararslan I, Dereli T. Hand-foot syndrome induced by capecitabine: case report. Turkiye Klinikleri J Dermatol 2009;19:214-7.
- 3. Karatay E, Akbal E, Koca D, et al. Kapesitabin tedavisi alan hastada gelişen atipik el ayak sendromu: olgu sunumu. Turk Onkol Dergisi. 2008; 23(3):140-1
- 4. Saif MW, Elfiky AA. Identifying and treating fluoropyrimidineassociated hand and foot syndrome in white and non-white patients. J Support Oncol 2007;5:337–43.
- 5. Uslu G , Karaman FG , Uslu M, et al. Metastatik meme karsinomu nedeniyle kapesitabin tedavisi alan hastada gelişen el-ayak sendromu. Turkderm 2006;40(3):105-7
- 6. Abushullaih S, Saad Ed, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single- institution experience. Cancer Invest 2002; 20:3-10.
- 7. Cassidy J , Twelves C , Van Cutsem E , et al. Capecitabine Colorectal Cancer Study Group. First line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.Ann Oncol 2002; 13:566-75. doi:10.1093/annonc/mdf089
- 8. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27:23- 44. doi:10.1016/j.clinthera.2005.01.005
- 9. Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs 2008; 19:447–64.
- 10. Mignogna MD, Fortuna G, Falleti J, Leuci S. Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis. Eur J Clin Pharmacol 2009; 65: 1057- 9. doi:10.1007/s00228-009-0674-z
- 11. Tavares-Bello R. Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient. J Eur Acad Dermatol Venereol. 2007; 21: 1434- 5. doi:10.1111/j.1468- 3083.2007.02242.x
- 12. Jeung HCl, Chung HC..Is pyridoxine helpful in preventing palmarplantar erythrodysesthesia associated with capecitabine? Asia Pac J Clin Oncol 2010;6: 141–3. doi: 10.1111/j.1743-7563.2010.01326.x
Metastatik Kolon Karsinomu Tedavisinde Kapesitabin'e Bağlı Ağır Oral Lezyonların Eşlik Ettiği El-Ayak Sendromu
Abstract
El-ayak sendromu (EAS) bazı kemoterapötiklerin yan etkisi olarak dizestezi,
keskin kenarlı plaklarla ve palmoplantar alanlarda simetrik lezyonlar şeklinde
görünür. Olgumuz ileri evre metastatik karsinom için kapesitabin
tedavisinin üçüncü döngüsünde avuç içi ve ayak tabanlarında hafif eritem
ve deskuamasyon gelişen, 68 yaşındaki erkek hastadır. Bu olgu sunumu ile
kapesitabin kemoterapisi alan hastalarda gelişebilen EAS konusuna dikkat
çekmeyi ve bilinç düzeyini yükseltmeyi amaçladık. Günümüz literatüründe
ağız mukozasında hemorajik bül oluşumu hakkında bilgiye rastlanmaması
nedeniyle olgumuz dikkat çekicidir
References
- 1. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004:31-40 doi:10.1016/j.ejon.2004.06.007
- 2. Turkmen M, Gerceker Turk B, Kılınc Kararslan I, Dereli T. Hand-foot syndrome induced by capecitabine: case report. Turkiye Klinikleri J Dermatol 2009;19:214-7.
- 3. Karatay E, Akbal E, Koca D, et al. Kapesitabin tedavisi alan hastada gelişen atipik el ayak sendromu: olgu sunumu. Turk Onkol Dergisi. 2008; 23(3):140-1
- 4. Saif MW, Elfiky AA. Identifying and treating fluoropyrimidineassociated hand and foot syndrome in white and non-white patients. J Support Oncol 2007;5:337–43.
- 5. Uslu G , Karaman FG , Uslu M, et al. Metastatik meme karsinomu nedeniyle kapesitabin tedavisi alan hastada gelişen el-ayak sendromu. Turkderm 2006;40(3):105-7
- 6. Abushullaih S, Saad Ed, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single- institution experience. Cancer Invest 2002; 20:3-10.
- 7. Cassidy J , Twelves C , Van Cutsem E , et al. Capecitabine Colorectal Cancer Study Group. First line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.Ann Oncol 2002; 13:566-75. doi:10.1093/annonc/mdf089
- 8. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27:23- 44. doi:10.1016/j.clinthera.2005.01.005
- 9. Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs 2008; 19:447–64.
- 10. Mignogna MD, Fortuna G, Falleti J, Leuci S. Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis. Eur J Clin Pharmacol 2009; 65: 1057- 9. doi:10.1007/s00228-009-0674-z
- 11. Tavares-Bello R. Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient. J Eur Acad Dermatol Venereol. 2007; 21: 1434- 5. doi:10.1111/j.1468- 3083.2007.02242.x
- 12. Jeung HCl, Chung HC..Is pyridoxine helpful in preventing palmarplantar erythrodysesthesia associated with capecitabine? Asia Pac J Clin Oncol 2010;6: 141–3. doi: 10.1111/j.1743-7563.2010.01326.x
There are 12 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Authors | |
| Publication Date | April 21, 2015 |
| IZ | https://izlik.org/JA94UF93ZW |
| Published in Issue | Year 2011 Volume: 24 Issue: 3 |